9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.

      American journal of respiratory and critical care medicine

      Aged, Anti-Bacterial Agents, therapeutic use, Anti-Inflammatory Agents, administration & dosage, C-Reactive Protein, analysis, Community-Acquired Infections, drug therapy, Double-Blind Method, Female, Follow-Up Studies, Hospitalization, Humans, Hydrocortisone, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Multiple Organ Failure, classification, Oxygen, blood, Placebos, Pneumonia, Radiography, Thoracic, Shock, Septic, Survival Rate

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications. In a multicenter trial, patients admitted to the Intensive Care Unit (ICU) with severe community-acquired pneumonia received protocol-guided antibiotic treatment and were randomly assigned to hydrocortisone infusion or placebo. Hydrocortisone was given as an intravenous 200-mg bolus followed by infusion at a rate of 10 mg/hour for 7 days. Primary end-points of the study were improvement in Pa(O(2)):FI(O(2)) (Pa(O(2)):FI(O(2)) > 300 or >/= 100 increase from study entry) and multiple organ dysfunction syndrome (MODS) score by Study Day 8 and reduction in delayed septic shock. Forty-six patients entered the study. At study entry, the hydrocortisone group had lower Pa(O(2)):FI(O(2)), and higher chest radiograph score and C-reactive protein level. By Study Day 8, treated patients had, compared with control subjects, a significant improvement in Pa(O(2)):FI(O(2)) (p = 0.002) and chest radiograph score (p < 0.0001), and a significant reduction in C-reactive protein levels (p = 0.01), MODS score (p = 0.003), and delayed septic shock (p = 0.001). Hydrocortisone treatment was associated with a significant reduction in length of hospital stay (p = 0.03) and mortality (p = 0.009).

          Related collections

          Author and article information

          Journal
          15557131
          10.1164/rccm.200406-808OC

          Comments

          Comment on this article